Analysis of the mechanism of action and pharmacological properties of Opicapone

As a third-generation COMT inhibitor, Opicapone's main pharmacological mechanism is to inhibit the degradation and metabolism of levodopa in peripheral tissues by blocking the activity of the COMT enzyme, thereby extending the half-life of levodopa and improving its stability in plasma, thereby promoting more active drugs to cross the blood-brain barrier and enhancing the dopamine effect of the central nervous system. Since COMT is one of the main peripheral metabolism channels of levodopa, after it is inhibited, the bioavailability of levodopa in the body is significantly improved, effectively reducing the "cross-over phenomenon".

Compared with the old generationCOMT inhibitors, Opicapone has unique high selectivity and long-lasting effect. It has extremely strong affinity at the enzyme binding site. Even though its half-life in the body is not long, its inhibitory effect on the enzyme can last for 24 hours, so it only needs to be taken once a day to maintain sufficient efficacy. It is not absorbed in the intestine but metabolized in the liver, avoiding direct effects on the central nervous system and reducing nervous system toxicity. Moreover, Opicapone is not prone to cross-inhibition with other enzyme systems and is well compatible with other Parkinson's disease medications (such as dopa decarboxylase inhibitors and MAO-B inhibitors).

In terms of pharmacokinetics, Opicapone is mainly metabolized by the liver and excreted in the bile. Its metabolites are inactive, which also greatly reduces the risk of drug accumulation and toxicity. In addition, opicapone does not enter the central nervous system, so most of its adverse effects originate from peripheral mechanisms, such as exacerbation of gastrointestinal symptoms or levodopa-related side effects. It is precisely because of these advantages that opicapone is gradually considered to be one of the most ideal COMT inhibitors at present, and has a unique position in the combined treatment of Parkinson's disease.

Reference materials:https://www.ongentys.com/